ANCA Vasculitis: Evolving Strategies Target Remission & Relapse Prevention

ANCA-associated vasculitis (AAV) is a group of systemic autoimmune diseases characterized by necrotizing inflammation of small blood vessels, often affecting the kidneys, lungs, and upper respiratory tract. The standard of care for induction of remission has historically involved cyclophosphamide combined with high-dose glucocorticoids, followed by a maintenance phase with agents like azathioprine or methotrexate. While effective in inducing remission, this approach carries significant risks, including infection, infertility, and malignancy, particularly with prolonged cyclophosphamide exposure.¹ The high rate of relapse, affecting up to 50% of patients within five years, further complicates management, necessitating strategies that balance efficacy with safety.²

AAV encompasses two main forms: granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA), distinguished by clinical presentation and ANCA serotype (PR3-ANCA in GPA, MPO-ANCA in MPA). The incidence of AAV varies geographically but is estimated to be between 10 and 20 cases per million per year, with a slight male predominance and a peak incidence in the sixth and seventh decades of life. The disease can manifest with a wide spectrum of symptoms, from constitutional symptoms like fever and weight loss to life-threatening organ damage, particularly rapidly progressive glomerulonephritis and diffuse alveolar hemorrhage. Early diagnosis and prompt initiation of immunosuppressive therapy are critical to prevent irreversible organ damage and reduce mortality. However, the chronic nature of AAV and the need for long-term immunosuppression underscore the importance of minimizing treatment-related toxicities while maintaining disease control.

Evolving Treatment Paradigms

Recent clinical trials have explored alternative induction and maintenance therapies to improve the risk-benefit profile for patients with AAV. One significant development has been the integration of rituximab, a B-cell depleting monoclonal antibody, into induction regimens. Early studies established rituximab's non-inferiority to cyclophosphamide for inducing remission in newly diagnosed severe AAV. For instance, a pivotal trial demonstrated that rituximab achieved remission in 64% of patients at 6 months, compared to 67% with cyclophosphamide (p=0.48), with similar rates of severe adverse events.³ This trial, known as RAVE, enrolled patients with newly diagnosed, severe AAV, including those with renal involvement, and randomized them to receive either rituximab or cyclophosphamide, both in combination with glucocorticoids. Subsequent long-term data confirmed sustained remission rates were comparable between the two groups at 18 months, supporting rituximab's role as an effective alternative.⁴

The utility of rituximab has expanded beyond induction to maintenance therapy. Studies comparing rituximab to azathioprine for maintaining remission have shown superior efficacy for rituximab. One trial reported that rituximab reduced the risk of major relapse by 36% compared to azathioprine over 28 months (HR 0.64, 95% CI 0.41-0.99, p=0.047).⁵ This evidence supports the use of rituximab for both induction and maintenance, particularly in patients with relapsing disease or those intolerant to conventional immunosuppressants. The dosing and duration of rituximab maintenance remain areas of ongoing investigation, with various regimens explored to optimize efficacy and minimize cost.⁶ For example, some studies have investigated fixed-interval dosing versus ANCA-driven retreatment strategies, aiming to personalize therapy based on individual patient characteristics and disease activity. These studies often include diverse patient populations, encompassing both PR3-ANCA and MPO-ANCA positive individuals, and those with varying degrees of organ involvement.

Beyond rituximab, newer targeted therapies are emerging. Avacopan, an oral C5a receptor inhibitor, has shown promise as a glucocorticoid-sparing agent. A phase 3 trial demonstrated that avacopan, when added to standard therapy, was non-inferior to glucocorticoid tapering for inducing remission at week 26 (remission rate 72.3% vs 70.1%, p<0.001 for non-inferiority). Importantly, avacopan-treated patients experienced significantly fewer glucocorticoid-related adverse events.⁷ This suggests avacopan could reduce the cumulative glucocorticoid burden, a major driver of morbidity in AAV. Avacopan's mechanism of action involves blocking the C5a receptor, thereby inhibiting the pro-inflammatory effects of C5a, a potent anaphylatoxin implicated in the pathogenesis of AAV. Other biologics targeting specific inflammatory pathways are also under investigation, aiming to further refine treatment and personalize care.⁸

Despite these advancements, challenges remain. The optimal duration of maintenance therapy, the management of refractory disease, and the long-term safety profiles of newer agents require further elucidation. Real-world data collection is crucial to understand how these evolving strategies translate into diverse clinical settings and patient populations. Furthermore, identifying biomarkers that predict treatment response or relapse risk could enable more precise, individualized therapy.⁹ Limitations in current research include the relatively short follow-up periods in some trials, which may not fully capture long-term safety and efficacy, especially regarding rare adverse events or late relapses. The generalizability of trial results to all AAV patients, particularly those with severe comorbidities or specific ethnic backgrounds, also warrants further investigation. Future research will likely focus on combination therapies, personalized medicine approaches, and the development of novel agents that specifically target the underlying immunological dysregulation in AAV without broad immunosuppression.